Precision biosciences stock.

7 ngày trước ... ... Precision BioSciences' common stock at $0.42 each. The stock option comes with a vesting schedule spread over four years, with one-quarter ...Avidity Biosciences ( RNA) stock is jumping over 15% in early trading after announcing that its alliance with Bristol-Myers Squibb ( BMY) had been greatly …The Precision BioSciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Precision BioSciences, Inc. (NASDAQ:DTIL) shares have had a horrible month, losing 29% after a relatively good period beforehand.For any long-term shareholders, the last month ends a year to forget by locking in a 60% share price decline. After such a large drop in price, Precision BioSciences may be sending very bullish signals at the …

The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […]Precision BioScience (NASDAQ: DTIL) stock is rallying for a second straight day after the company announced a new partnership with Novartis (NYSE: NVS) after market close yesterday. Novartis is a ...

Dec 1, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Precision BioSciences stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for DTIL. The average twelve-month price prediction for Precision BioSciences is $3.00 with a high price target of $4.00 and a low price target of $2.00.

Dec 1, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Precision BioSciences stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for DTIL. The average twelve-month price prediction for Precision BioSciences is $3.00 with a high price target of $4.00 and a low price target of $2.00. Precision BioSciences is a clinical stage gene editing company that develops CAR T immunotherapies and gene insertion therapies for genetic and infectious …Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and ...

November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...

Precision BioSciences presents Q4 figures on March 15. Analysts are expecting losses per share of $0.473. Watch Precision BioSciences stock price move in real-time ahead here.

Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.60Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...DTIL Precision BioSciences Inc Form 8-K - Current report. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...The stock currently has a share float of 51.43%. Precision Biosciences Inc stock is held by 114 institutions, with Great Point Partners LLC being the largest institutional investor. By Jun 29, 2023, it held 6.49% of the shares, which is about 7.47 million shares worth $3.93 million.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).. The company announced the promotion of Neil …Nov 17, 2023 · In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ... Precision BioSciences (NASDAQ: DTIL ), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for ...DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...

About us. Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its …

Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …16 thg 8, 2023 ... Precision BioSciences hands global rights to CAR-T candidate; Sagimet closes underwriter's option to buy stock ... Precision BioSciences said ...Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …We would like to show you a description here but the site won’t allow us.On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.DTIL's stock price has decreased by -71.36% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 3 stock analysts, the average 12-month stock price forecast for DTIL stock stock is $3.00, which predicts an increase of 607.88%.Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update. March 15, 2022 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding - basic and diluted 58,688,102 52,031,740 Precision Biosciences, Inc. Consolidated Balance Sheets Data ...

If you are looking for stocks with good return, Precision Biosciences Inc stock can be a bad, high-risk 1-year investment option. Precision Biosciences Inc real time quote is equal to 0.363 USD at 2023-12-03, but your current investment may be devalued in the future.

3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ...Precision BioSciences Inc. 0.3787. Delayed Data. As of Nov 10. -0.0153 / -3.88%. Today’s Change. 0.28. Today ||| 52-Week Range.On December 4, 2023, Precision Biosciences made a groundbreaking announcement in the esteemed journal Nature Metabolism. The publication highlighted their latest …Detailed annual and quarterly income statement for Precision BioSciences, Inc. (DTIL). See many years of revenue, expenses and profits or losses. ... Stock Analysis Pro. Watchlist. Collapse. Precision BioSciences, Inc. (DTIL) NASDAQ: DTIL · IEX Real-Time Price · USD. Add to Watchlist 0.384Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Precision BioSciences Inc stock performance at a glance. Check Precision BioSciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. DTIL Stock Performance. USD USD; Previous close: 0.437: 0.437: Day range: 0.44 - 0.470.44 - 0.47Year range: 0 - 10 - 1In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Precision BioSciences will be entitled to receive an upfront payment of $75 million from NVS. The company is also eligible to receive up to an additional $1.4 billion as future milestone payments ...Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding Instagram:https://instagram. automated trading brokerscox and dodgeraytheon stock chartcredit suisse stocks The Precision BioSciences stock prediction for 2025 is currently $ 0.180111, assuming that Precision BioSciences shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -53.10% increase in the DTIL stock price.About Precision BioSciences, Inc. ... risks related to ownership of our common stock and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10 ... day trading programschwab emerging markets etf The general public, who are usually individual investors, hold a 29% stake in Precision BioSciences. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Public Company Ownership. Public companies currently own 15% of Precision BioSciences …Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More. is td ameritrade good for forex Precision BioSciences is a clinical stage gene editing company that develops CAR T immunotherapies and gene insertion therapies for genetic and infectious …Nov 7, 2023 · November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,... Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...